AUSTIN, Texas and TOKYO, Oct. 7, 2025 /PRNewswire/ -- The Multi Cancer Early Detection Testing (MCED) Market is entering a high-growth phase as precision diagnostics and liquid biopsy technologies redefine cancer care. According to DataM Intelligence, the Multi Cancer Early Detection Testing Market Size reached US$ 1.67 billion in 2023, rose to US$ 1.92 billion in 2024, and is projected to grow to US$ 7.52 billion by 2033, expanding at a CAGR of 16.5% during 2025–2033.
Cancer continues to be the leading cause of mortality worldwide, with nearly 10 million deaths annually. Traditional screening methods are cancer-specific, costly, and often invasive, leading to late-stage diagnoses that limit survival outcomes. MCED tests-using liquid biopsies, genomic signatures, and AI-powered analysis-offer the ability to detect multiple cancers from a single blood draw, even before symptoms appear.
Global adoption is accelerating, led by GRAIL's Galleri Test, Guardant Health's liquid biopsy platforms, and Exact Sciences' precision oncology solutions. Investments from Roche's Foundation Medicine and biotech innovators such as Burning Rock, Lucence Health, and Freenome are further shaping the competitive landscape.
Download Exclusive Sample Report: https://www.datamintelligence.com/download-sample/multi-cancer-early-detection-testing-market
Browse in-depth TOC on 'Multi Cancer Early Detection Testing Market'
70 – Tables
66 – Figures
195 – Pages
Market Segmentation Analysis
By Test Type
Galleri Test, pioneered by GRAIL, dominated the market with over 40% share (US$ 770 million in 2024). Its ability to detect over 50 types of cancers with high specificity has made it the benchmark in MCED adoption across the U.S. and Europe.
CancerSEEK, developed through partnerships involving Johns Hopkins, captured 25% of the market (US$ 480 million). The test is expanding rapidly in colorectal, ovarian, and lung cancer detection.
By Cancer Type
Breast cancer led the segment in 2024 (US$ 420 million), supported by early detection programs in the U.S. and Japan.
Colorectal cancer and lung cancer together contributed US$ 620 million, as liquid biopsy solutions gain traction over invasive colonoscopies and imaging scans.
Blood cancers and prostate cancers, valued at US$ 480 million combined, are benefiting from MCED's non-invasive detection advantages.
By End-User
Hospitals & Clinics accounted for US$ 950 million in 2024, reflecting their role as the primary hubs for early cancer diagnosis.
Diagnostic laboratories generated US$ 690 million, with large lab chains partnering with biotech firms to expand access.
Academic & research institutes, valued at US$ 280 million, remain critical for clinical validation, biomarker discovery, and regulatory pathway advancement.
Regional Insights: USA & Japan
United States
The U.S. leads the MCED market with revenues exceeding US$ 920 million in 2024. Growth is fueled by:
Japan
Japan's MCED market, valued at US$ 190 million in 2024, is gaining momentum due to:
Request for Customized Sample Report as per Your Business Requirement: https://www.datamintelligence.com/download-sample/multi-cancer-early-detection-testing-market
Industry Trends & 2025 Developments
Competitive Landscape
GRAIL
GRAIL leads the MCED space with its Galleri Test, currently the most widely validated early detection test. Backed by Illumina and industry partnerships, GRAIL is expanding across North America, Europe, and Asia.
Guardant Health
Guardant has established itself as a liquid biopsy leader, leveraging genomic sequencing to detect early-stage cancers. In 2025, the company enhanced its MCED portfolio with AI-powered detection of gastrointestinal cancers.
Exact Sciences
Known for its Cologuard® test, Exact Sciences is expanding into MCED through partnerships with research institutes. Its multi-analyte testing platforms are positioned to capture share in colorectal and pancreatic cancers.
Burning Rock Biotech & Lucence Health
These companies are driving innovation in Asia, focusing on cost-effective, scalable MCED solutions. Their tests are gaining regulatory traction in Japan and China.
Roche's Foundation Medicine
Foundation Medicine brings strong diagnostic credibility, with 2025 developments focused on integrating MCED into comprehensive genomic profiling solutions.
Strategic Outlook
The MCED market is at a pivotal stage of evolution. Four themes define its future trajectory:
Buy This Exclusive Report at Just USD 4350 Only: https://www.datamintelligence.com/buy-now-page?report=multi-cancer-early-detection-testing-market
Conclusion
The Multi Cancer Early Detection Testing Market, projected to grow from US$ 1.92 billion in 2024 to US$ 7.52 billion by 2033, is redefining global cancer care. With Galleri, CancerSEEK, Guardant Health, and Exact Sciences leading the innovation curve, MCED is positioned to transform survival outcomes by shifting cancer detection from late-stage diagnosis to early intervention.
Related Report:
About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
Back | Next story: PureHealth completes EUR 800 million acquisition of Hellenic Healthcare Group, strengthening its global platform
View original content: